Product logins

Find logins to all Clarivate products below.


Binge Eating Disorder – Epidemiology – Binge Eating Disorder

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of BED for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

Clarivate Epidemiology’s BED forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BED over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 BED patient populations, as follows:

  • Total lifetime prevalent cases of BED.
  • Total 12-month prevalent cases of BED.
  • Total lifetime prevalent cases of mild BED.
  • Total lifetime prevalent cases of moderate BED.
  • Total lifetime prevalent cases of severe BED.
  • Total lifetime prevalent cases of extreme BED.
  • Total lifetime prevalent cases of BED with depression.
  • Total lifetime prevalent cases of BED with anxiety disorder.
  • Total lifetime prevalent cases of BED with bipolar disorder.
  • Total lifetime prevalent cases of BED with attention-deficit/hyperactivity disorder.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…